The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PMCB | -47.71% | -88.33% | -34.9% | -100% |
| S&P | +16.49% | +84.25% | +12.99% | +572% |
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
No news articles found for PharmaCyte Biotech.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $6.32M | -54.5% |
| Market Cap / Employee | $3.16M | 0.0% |
| Employees | 2 | 0.0% |
| Net Income | -$7,417.98K | -404.8% |
| EBITDA | -$1,376.05K | -24.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.41M | -26.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -12.74% | -46.6% |
| Return On Invested Capital | -0.78% | 26.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$979.52K | 7.1% |
| Operating Free Cash Flow | -$979.52K | 7.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 2.90 | 3.32 | 2.11 | 0.46 | - |
| Price to Book | 0.26 | 0.21 | 0.17 | 0.14 | -50.48% |
| Price to Tangible Book Value | 0.27 | 0.22 | 0.18 | 0.15 | -50.33% |
| Enterprise Value to EBITDA | 5.82 | 6.83 | 7.67 | 6.09 | -3.95% |
| Return on Equity | 45.4% | 67.1% | -2.3% | -17.8% | -139.78% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
